Guinan P - Search Results

1

Lack of toxicity associated with the systemic administration of antisense oligonucleotides for treatment of rats bearing LNCaP prostate tumors.

Rubenstein M, Mirochnik Y, Ray V, Guinan P. Rubenstein M, et al. Among authors: guinan p. Med Oncol. 1997 Sep-Dec;14(3-4):131-6. doi: 10.1007/BF02989639. Med Oncol. 1997. PMID: 9468034

2

Inhibition of PC-3 prostate cancer cell growth in vitro using both antisense oligonucleotides and taxol.

Rubenstein M, Slobodskoy L, Mirochnik Y, Guinan P. Rubenstein M, et al. Among authors: guinan p. Med Oncol. 2003;20(1):29-35. doi: 10.1385/MO:20:1:29. Med Oncol. 2003. PMID: 12665682

3

Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model.

Tsui P, Rubenstein M, Guinan P. Tsui P, et al. Among authors: guinan p. Med Oncol. 2004;21(4):339-48. doi: 10.1385/MO:21:4:339. Med Oncol. 2004. PMID: 15579918

4

Targeting of biotinylated oligonucleotides to prostate tumors with antibody-based delivery vehicles.

Mirochnik Y, Rubenstein M, Guinan P. Mirochnik Y, et al. Among authors: guinan p. J Drug Target. 2007 Jun;15(5):342-50. doi: 10.1080/10611860701350099. J Drug Target. 2007. PMID: 17541843

5

Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.

Rubenstein M, Tsui P, Guinan P. Rubenstein M, et al. Among authors: guinan p. Med Oncol. 2007;24(2):189-96. doi: 10.1007/BF02698039. Med Oncol. 2007. PMID: 17848743

6

Combination chemotherapy employing bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.

Rubenstein M, Tsui P, Guinan P. Rubenstein M, et al. Among authors: guinan p. Med Oncol. 2007;24(4):372-8. doi: 10.1007/s12032-007-0023-y. Med Oncol. 2007. PMID: 17917084

7

Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2.

Rubenstein M, Tsui P, Guinan P. Rubenstein M, et al. Among authors: guinan p. Med Oncol. 2008;25(2):182-6. doi: 10.1007/s12032-007-9018-y. Epub 2007 Oct 30. Med Oncol. 2008. PMID: 17972023

8

Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.

Rubenstein M, Tsui P, Guinan P. Rubenstein M, et al. Among authors: guinan p. Med Oncol. 2009;26(2):124-30. doi: 10.1007/s12032-008-9088-5. Epub 2008 Aug 7. Med Oncol. 2009. PMID: 18686047

9

Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2.

Rubenstein M, Tsui P, Guinan P. Rubenstein M, et al. Among authors: guinan p. Med Oncol. 2010 Sep;27(3):592-9. doi: 10.1007/s12032-009-9254-4. Epub 2009 Jun 16. Med Oncol. 2010. PMID: 19533419

10

Increased prostate-specific membrane antigen expression in LNCaP cells following treatment with bispecific antisense oligonucleotides directed against bcl-2 and EGFR.

Rubenstein M, Hollowell CM, Guinan P. Rubenstein M, et al. Among authors: guinan p. Med Oncol. 2010 Dec;27(4):1212-8. doi: 10.1007/s12032-009-9361-2. Epub 2009 Nov 24. Med Oncol. 2010. PMID: 19937163

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

269 results

Search Page

Filters